2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-118151
    Rho-Kinase-IN-3 864082-23-5 99.74%
    Rho-Kinase-IN-3 (compound 12) is a potent and selective Rho kinase (ROCK1) inhibitor with an IC50 value of 8 nM. Rho-Kinase-IN-3 can be used in research of hypertension.
    Rho-Kinase-IN-3
  • HY-118332
    19(R)-HETE 115461-39-7 98.20%
    19(R)-HETE is a vasodilator in renal arteries, whereas 19(S)-HETE was relatively inactive.
    19(R)-HETE
  • HY-119442
    Quininib 143816-42-6 98.1%
    Quininib is a cysteinyl leukotriene 1 and 2 receptor antagonist with IC50s of 1.2 and 52 μM for CysLT1R and CysLT2R, respectively. Quininib is a potent inhibitor of developmental angiogenesis in the zebrafish eye. Quininib can be used for the research of ocular neovascular pathologies and may complement current anti-VEGF biological agents.
    Quininib
  • HY-119855
    Aildenafil 496835-35-9 98.46%
    Aildenafil (Methisosildenafil) is a PDE-5 inhibitor that can induce vasodilation by increasing NO levels.
    Aildenafil
  • HY-120178
    (±)7(8)-DiHDPA 168111-93-1 98.00%
    (±)7(8)-DiHDPA is a epoxygenase metabolite of docosahexaenoic acid (HY-B2167). (±)7(8)-DiHDPA inhibits platelet aggregation at concentrations below those affecting thromboxane synthesis.
    (±)7(8)-DiHDPA
  • HY-121837
    β2AR-IN-15 2088234-50-6 98.84%
    β2AR-IN-15 is a selective β2-adrenergic receptor (β2AR) antagonist with a Kd of 1.7 μM. β2AR-IN-15 binds to an intracellular β2AR region overlapping the G-protein binding site, enhancing orthosteric inverse agonist binding while negatively modulating binding of orthosteric agonists with EC50 values of 1.9 and 0.48 μM. β2AR-IN-15 shows inhibitory effect on cAMP production and β-arrestin recruitment to activated β2AR. β2AR-IN-15 can be used for the research of cardiovascular and pulmonary diseases.
    β2AR-IN-15
  • HY-122405
    Quebrachidine 4835-69-2
    Quebrachidine is an indole alkaloid that exhibits antiarrhythmic profile. Quebrachidine also demonstrates a net positive inotropic action on cardiac tissues.
    Quebrachidine
  • HY-123744
    PD-156707 162412-70-6 99.92%
    PD-156707 is an orally active, nonpeptide and selective Endothelin-A receptor antagonist. PD-156707 binds to human ET-A and ET-B receptors with Ki values of 0.17 nM and 133.8 nM, respectively. PD-156707 shows reversal of established chronic hypoxic pulmonary hypertension in rats. PD-156707 can be used for the study of diseases associated with abnormal ET-A receptor activation, particularly pulmonary hypertension, stroke, and heart failure.
    PD-156707
  • HY-12805R
    ML171 (Standard) 6631-94-3 98.62%
    ML171 (Standard) is the analytical standard of ML171. This product is intended for research and analytical applications. ML171 (2-Acetylphenothiazine;2-APT) is a potent and selective NADPH oxidase 1 (Nox1) inhibitor that blocks Nox1-dependent ROS generation, with an IC50 of 0.25 μM in HEK293-Nox1 confirmatory assay.
    ML171 (Standard)
  • HY-129883
    (3R)-Hydroxyquinidine 60761-51-5 98%
    (3R)-Hydroxyquinidine is the major metabolite of Quinidine (HY-B1751).
    (3R)-Hydroxyquinidine
  • HY-129899
    (±)-Equol 4'-sulfate sodium 1189685-28-6 ≥99.0%
    (±)-Equol 4'-sulfate sodium is a metabolite of the isoflavonoid phytoestrogen (±)-Equol (HY-100583A) .
    (±)-Equol 4'-sulfate sodium
  • HY-133594
    Sandaracopimaric acid 471-74-9 98.86%
    Sandaracopimaric acid is a diterpenoid with anti-inflammatory effect. Sandaracopimaric acid reduces the contraction of phenylephrine-induced pulmonary arteries with an EC50 of 43.93 μM.
    Sandaracopimaric acid
  • HY-13866A
    Ro 31-8220 125314-64-9 98%
    Ro 31-8220 is a potent PKC inhibitor, with IC50s of 5, 24, 14, 27, 24 and 23 nM for PKCα, PKCβI, PKCβII, PKCγ, PKCε and rat brain PKC, respectively. Ro 31-8220 also significantly inhibits MAPKAP-K1b, MSK1, S6K1 and GSK3β (IC50s, 3, 8, 15, and 38 nM, respectively), with no effect on MKK3, MKK4, MKK6 and MKK7. Ro 31-8220 can also inhibit the expression of MKP-1, induce the expression of c-Jun, and activate JNK, and these effects possess pharmacological properties independent of PKC.
    Ro 31-8220
  • HY-139177
    PPARα agonist 2 2376590-40-6 98.9%
    PPARα agonist 2 (compound 4u) is a potent and selective PPARα agonist with an EC50 of 37 nM. PPARα agonist 2 exhibits >2,700-fold selectivity for PPARα over other PPAR isoforms. PPARα agonist 2 has the potential for retinal disorders research.
    PPARα agonist 2
  • HY-141436
    Sucrosofate potassium 73264-44-5 98.0%
    Sucrosofate potassium (Sucrose octasulfate potassium) is a wound healing promoter. Sucrosofate potassium inhibits MMP, promotes angiogenesis and improves microcirculation. Sucrosofate potassium causes mild skin irritation. Sucrosofate potassium can be used to prepare p (MMA-co-AM)/PVA@PSO hydrogels. Sucrosofate potassium is applicable to research related to diabetic wounds.
    Sucrosofate potassium
  • HY-141469
    6,9,12,15,18-Heneicosapentaenoic acid 65919-53-1 99.4%
    6,9,12,15,18-Heneicosapentaenoic acid (HPA) is a ∆5 desaturase inhibitor. 6,9,12,15,18-Heneicosapentaenoic acid serves as a weak substrate for Prostaglandin H synthase and 5-lipoxygenase, yet it inactivates Prostaglandin H synthase at a rate comparable to that of AA, EPA and DHA. 6,9,12,15,18-Heneicosapentaenoic acid is a weak inducer of Aacyl-CoA oxidase. 6,9,12,15,18-Heneicosapentaenoic acid incorporates into phospholipids and triacylglycerols in cell culture. 6,9,12,15,18-Heneicosapentaenoic acid can be used in research related to liver cancer.
    6,9,12,15,18-Heneicosapentaenoic acid
  • HY-14184R
    Macitentan (Standard) 441798-33-0 99.79%
    Macitentan (Standard) is the analytical standard of Macitentan. This product is intended for research and analytical applications. Macitentan (ACT-064992) is an orally active, non-peptide dual ETA and ETB (endothelin receptor) antagonist. Macitentan has the potential for idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).
    Macitentan (Standard)
  • HY-147357
    TRPC3/6-IN-1 736945-96-3 98%
    TRPC3/6-IN-1 is a potent selectivity blocker of the canonical transient receptor channels (TRPC3/6), has block potency for hTRPC3 and hTRPC6 with IC50 values of 1260 nM and 500 nM, respectively. TRPC3/6-IN-1 can be used for the research of chronic models of heart failure.
    TRPC3/6-IN-1
  • HY-153860
    LacCer (d18:1/20:0) 125650-87-5 99.94%
    LacCer (d18:1/20:0) is a lipid whose level is closely associated with atherosclerosis and cardiovascular diseases.
    LacCer (d18:1/20:0)
  • HY-15407R
    Sacubitril (Standard) 149709-62-6 98%
    Sacubitril (Standard) is the analytical standard of Sacubitril. This product is intended for research and analytical applications. Sacubitril (AHU-377) is a potent and orally active NEP (neprilysin) inhibitor with an IC50 of 5 nM. Sacubitril is a component of the heart failure medicine LCZ696. Sacubitril can be used for the research of heart failure, hypertension and COVID-19.
    Sacubitril (Standard)
Cat. No. Product Name / Synonyms Application Reactivity